Free Trial
→ Genesis 14:13-17 [HIDDEN MEANING?] (From Paradigm Press) (Ad) Free GYRE Stock Alerts

Gyre Therapeutics (GYRE) Financials

Gyre Therapeutics logo
$7.38 -0.19 (-2.51%)
Closing price 04:00 PM Eastern
Extended Trading
$7.49 +0.11 (+1.49%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Gyre Therapeutics

Annual Income Statements for Gyre Therapeutics

This table shows Gyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.61 -15 -17 -26 -30 -55 -56 -88 2.30 -93 12
Consolidated Net Income / (Loss)		 -6.61 -15 -17 -22 -30 -55 -56 -88 4.31 -85 18
Net Income / (Loss) Continuing Operations		 -6.61 -15 -17 -22 -30 -55 -56 -88 4.31 -85 18
Total Pre-Tax Income 		-6.61 -15 -17 -22 -30 -55 -56 -88 9.41 -77 23
Total Operating Income		 -7.51 -14 -20 -22 -34 -57 -57 -88 9.20 -67 16
Total Gross Profit		 1.81 1.75 0.40 1.02 0.01 0.00 12 -0.04 97 109 102
Total Revenue		 1.81 1.75 0.40 1.02 0.01 0.00 21 7.34 102 113 106
Operating Revenue		 1.81 1.75 0.40 1.02 0.01 0.00 21 7.34 102 113 106
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 9.16 7.38 4.79 4.64 3.88
Operating Cost of Revenue		 - - - - - 0.00 9.16 7.38 4.79 4.64 3.88
Total Operating Expenses		 9.32 16 21 23 34 57 69 88 88 176 86
Selling, General & Admin Expense		 4.06 9.59 9.26 9.99 12 13 16 19 17 15 16
Marketing Expense		 - - - - - - - - 54 61 58
Research & Development Expense		 5.27 5.96 12 13 21 44 53 69 17 97 12
Other Operating Expenses / (Income)		 - - - - - - - - - 2.71 0.00
Other Special Charges / (Income)		 - - - - - - - 0.00 0.00 0.63 0.07
Total Other Income / (Expense), net		 0.90 -0.96 3.47 0.26 3.77 2.10 1.13 -0.04 0.21 -9.74 7.06
Interest Expense		 -0.90 0.96 -3.47 -0.26 -3.77 -2.10 -1.13 0.04 -0.73 -1.04 -1.55
Other Income / (Expense), net		 - - - - - - - - -0.52 -11 5.51
Income Tax Expense		 - - - - - - - 0.00 5.10 8.52 5.32
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - - - 2.01 7.45 5.81
Basic Earnings per Share		 ($17.99) ($49.99) ($21.75) ($7.45) ($2.68) ($4.60) ($2.93) ($2.87) $0.04 ($1.41) $0.14
Weighted Average Basic Shares Outstanding		 367.59K 295.27K 779.17K 3.42M 11.21M 12.00M 19.18M 30.64M 63.59M 65.83M 85.09M
Diluted Earnings per Share		 ($17.99) ($49.99) ($21.75) ($7.45) ($2.68) ($4.60) ($2.93) ($2.87) $0.03 ($1.41) $0.05
Weighted Average Diluted Shares Outstanding		 367.59K 295.27K 779.17K 3.42M 11.21M 12.00M 19.18M 30.64M 75.69M 65.83M 102.29M
Weighted Average Basic & Diluted Shares Outstanding		 367.59K 295.27K 779.17K 3.42M 11.21M 12.00M 19.18M 30.64M 37.76M 85.42M 93.61M

Quarterly Income Statements for Gyre Therapeutics

This table shows Gyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.88 -30 2.24 1.85 3.98 -101 7.53 3.53 1.12 -0.10 2.70
Consolidated Net Income / (Loss)		 -4.88 -28 4.22 3.77 7.51 -101 9.94 4.54 2.86 0.57 3.73
Net Income / (Loss) Continuing Operations		 -4.88 -28 4.22 3.77 7.51 -101 9.94 4.54 2.86 0.57 3.73
Total Pre-Tax Income 		-4.88 -23 6.27 5.85 11 -100 12 6.04 3.93 0.77 4.64
Total Operating Income		 -5.17 -22 6.66 4.97 13 -92 8.07 3.26 4.23 0.60 2.27
Total Gross Profit		 0.00 98 24 28 31 26 26 24 25 27 21
Total Revenue		 0.00 101 25 29 32 27 27 25 25 28 22
Operating Revenue		 0.00 101 25 29 32 27 27 25 25 28 22
Total Cost of Revenue		 0.00 4.00 1.13 1.08 1.18 1.25 0.98 0.77 0.96 1.18 0.89
Operating Cost of Revenue		 0.00 4.00 1.13 1.08 1.18 1.25 0.98 0.77 0.96 1.18 0.89
Total Operating Expenses		 5.17 120 17 23 19 117 18 21 20 26 19
Selling, General & Admin Expense		 4.36 4.17 1.74 1.71 1.16 10 3.40 3.42 3.82 5.46 4.96
Marketing Expense		 - - 13 18 14 16 13 14 14 17 11
Research & Development Expense		 0.80 4.31 2.64 3.57 3.01 88 2.18 3.36 2.78 3.71 3.10
Total Other Income / (Expense), net		 0.28 -0.34 -0.39 0.88 -1.05 -9.17 4.41 2.84 -0.30 0.11 2.36
Other Income / (Expense), net		 - - -0.58 0.63 -1.33 -9.50 4.41 2.49 -0.83 -0.24 2.36
Income Tax Expense		 0.00 5.10 2.05 2.08 3.68 0.70 2.55 1.50 1.07 0.20 0.90
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 1.97 1.92 3.53 0.03 2.40 1.01 1.73 0.67 1.04
Basic Earnings per Share		 ($0.16) ($0.98) $0.04 $0.03 $0.06 ($1.54) $0.09 $0.04 $0.01 - $0.03
Weighted Average Basic Shares Outstanding		 31.48M 63.59M 63.59M 63.59M 63.59M 65.83M 83.27M 85.50M 85.64M 85.09M 86.42M
Diluted Earnings per Share		 ($0.16) ($0.99) $0.03 $0.02 $0.05 ($1.51) $0.03 $0.01 $0.01 - $0.00
Weighted Average Diluted Shares Outstanding		 31.48M 75.69M 78.92M 78.90M 78.90M 65.83M 102.59M 104.33M 102.64M 102.29M 101.97M
Weighted Average Basic & Diluted Shares Outstanding		 31.49M 37.76M 37.76M 37.97M 37.98M 85.42M 85.51M 93.42M 93.52M 93.61M 93.76M

Annual Cash Flow Statements for Gyre Therapeutics

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -1.28 28 -19 -10 11 -16 15 14 -5.03 8.33 -22
Net Cash From Operating Activities		 -6.39 -19 -18 -20 -29 -44 -55 -84 11 26 -3.64
Net Cash From Continuing Operating Activities		 -6.39 -19 -18 -20 -29 -44 -55 -84 11 26 -3.64
Net Income / (Loss) Continuing Operations		 -6.61 -15 -17 -22 -30 -55 -56 -88 4.31 -85 18
Consolidated Net Income / (Loss)		 -6.61 -15 -17 -22 -30 -55 -56 -88 4.31 -85 18
Depreciation Expense		 0.68 0.47 0.39 0.17 0.15 0.15 0.14 0.29 1.09 1.07 1.55
Amortization Expense		 - - - - - - - - 0.04 0.04 0.04
Non-Cash Adjustments To Reconcile Net Income		 0.02 1.43 -2.75 0.88 2.72 3.20 3.63 3.41 14 105 -11
Changes in Operating Assets and Liabilities, net		 -0.48 -6.26 0.84 0.57 -1.37 8.22 -2.57 0.48 -8.64 4.76 -13
Net Cash From Investing Activities		 0.10 37 -1.31 -11 -71 27 9.66 48 -14 -20 -20
Net Cash From Continuing Investing Activities		 0.10 37 -1.31 -11 -71 27 9.66 48 -14 -20 -20
Purchase of Property, Plant & Equipment		 0.00 -0.27 -0.47 -0.02 -0.38 - - -0.84 -4.99 -8.52 -2.32
Acquisitions		 - - - - - - - - -1.35 -1.19 -2.50
Sale of Property, Plant & Equipment		 0.10 0.00 2.56 - - - - 0.00 0.00 0.66 0.40
Divestitures		 - - - - - - - 0.00 0.00 5.59 0.00
Other Investing Activities, net		 0.00 24 -0.01 - - - - 0.00 -7.48 -16 -15
Net Cash From Financing Activities		 5.01 9.31 0.95 21 111 0.33 60 50 0.00 2.50 2.10
Net Cash From Continuing Financing Activities		 5.01 9.31 0.95 21 111 0.33 60 50 0.00 2.50 2.10
Repayment of Debt		 0.00 -3.02 -14 -14 -5.08 - - - - - 0.00
Repurchase of Preferred Equity		 - - - - - - - - 0.00 2.50 0.00
Issuance of Common Equity		 - 0.00 0.96 5.34 - 0.33 60 49 - 0.00 0.77
Other Financing Activities, net		 0.03 0.01 0.00 12 9.65 - - 0.30 - 0.00 1.33
Effect of Exchange Rate Changes		 - - - - - - - - -1.89 -0.30 -0.27
Cash Income Taxes Paid		 - - - - - - - - 6.31 6.35 8.52

Quarterly Cash Flow Statements for Gyre Therapeutics

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -52 16 2.97 -4.42 2.35 7.43 -3.72 -14 -0.23 -4.05 3.23
Net Cash From Operating Activities		 -7.28 42 10 4.53 7.58 3.36 2.88 -5.49 1.73 -2.76 -0.13
Net Cash From Continuing Operating Activities		 -7.28 42 10 4.53 7.58 3.36 2.88 -5.49 1.73 -2.76 -0.15
Net Income / (Loss) Continuing Operations		 -4.88 -28 4.22 3.77 7.51 -101 9.94 4.54 2.86 0.57 3.73
Consolidated Net Income / (Loss)		 -4.88 -28 4.22 3.77 7.51 -101 9.94 4.54 2.86 0.57 3.73
Depreciation Expense		 0.04 0.87 0.28 0.31 0.19 0.30 0.42 0.23 0.45 0.46 0.54
Amortization Expense		 - - 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.33 70 0.29 0.55 0.69 104 -4.36 -2.67 0.15 -3.61 1.38
Changes in Operating Assets and Liabilities, net		 -2.77 -0.43 5.63 -0.10 -0.82 0.06 -3.10 -7.60 -1.73 -0.18 -5.81
Net Cash From Investing Activities		 - -69 -7.65 -8.05 -5.40 1.34 -7.22 -8.27 -2.39 -2.00 1.97
Net Cash From Continuing Investing Activities		 - -69 -7.65 -8.05 -5.40 1.34 -7.22 -8.27 -2.39 -2.00 1.97
Purchase of Property, Plant & Equipment		 - - -1.74 -2.48 -1.97 -2.32 -0.23 -1.46 -0.69 0.07 -0.12
Acquisitions		 - - -0.07 -0.00 -0.00 -1.13 0.00 - -0.00 -2.50 -0.70
Purchase of Investments		 - - - - - - 0.00 - - - 0.00
Sale of Property, Plant & Equipment		 - -0.45 0.00 0.13 0.36 0.17 0.05 0.22 -0.01 0.14 0.00
Sale and/or Maturity of Investments		 - - - - - - 0.00 - - - 11
Other Investing Activities, net		 - -60 -5.84 -5.71 -2.79 -1.97 -7.04 -7.04 -1.69 0.29 -8.40
Net Cash From Financing Activities		 -45 45 0.00 - - 2.50 0.66 0.16 0.32 0.96 1.34
Net Cash From Continuing Financing Activities		 -45 45 0.00 - - 2.50 0.66 0.16 0.32 0.96 1.34
Repayment of Debt		 - - - - - - 0.00 - - - -0.12
Issuance of Common Equity		 - - - - - - 0.00 - - - 0.51
Other Financing Activities, net		 0.00 - 0.00 - - - 0.66 0.28 0.37 0.02 0.96
Effect of Exchange Rate Changes		 - - 0.20 -0.90 0.17 0.23 -0.05 -0.08 - - 0.05
Cash Income Taxes Paid		 - - 0.46 3.54 1.38 0.96 1.44 5.78 0.54 0.76 3.36

Annual Balance Sheets for Gyre Therapeutics

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 2.98 70 38 40 125 99 95 56 85 117 125
Total Current Assets		 2.07 69 38 39 124 96 90 51 50 57 65
Cash & Equivalents		 1.54 29 10 14 31 15 30 44 25 34 12
Short-Term Investments		 0.00 3.40 6.80 18 89 61 49 2.50 - 0.00 15
Note & Lease Receivable		 - - - - - - - - 17 0.39 9.33
Accounts Receivable		 0.10 0.49 0.03 - - 15 3.31 1.82 0.00 16 20
Inventories, net		 - - - - - - - - 6.12 4.28 6.34
Prepaid Expenses		 0.10 1.78 0.96 1.33 3.81 4.20 6.84 2.81 0.38 1.55 2.63
Plant, Property, & Equipment, net		 0.91 0.70 0.44 0.28 0.39 0.30 0.43 0.97 18 23 24
Total Noncurrent Assets		 0.00 0.13 0.13 0.13 0.54 2.18 4.90 3.22 17 36 37
Intangible Assets		 - - - - - - - - 0.30 0.21 0.27
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 4.08 4.70 5.62
Other Noncurrent Operating Assets		 - - 0.13 0.13 0.54 2.18 2.36 3.22 13 26 31
Total Liabilities & Shareholders' Equity		 2.98 70 38 40 125 99 95 56 85 117 125
Total Liabilities		 3.46 38 22 8.74 4.98 30 19 15 13 38 27
Total Current Liabilities		 2.34 38 22 8.74 4.80 29 18 14 12 20 20
Accounts Payable		 0.25 0.94 0.84 0.75 1.25 4.28 5.93 6.42 0.12 0.36 0.11
Accrued Expenses		 0.03 0.54 0.81 1.32 2.04 7.03 6.74 4.07 9.26 12 11
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - 2.10 5.05 2.83
Other Current Liabilities		 0.00 1.16 - - - 0.48 0.66 1.98 0.61 2.70 5.96
Total Noncurrent Liabilities		 1.12 0.34 0.05 0.00 0.17 1.32 0.98 0.41 0.29 18 7.49
Noncurrent Deferred Revenue		 0.73 0.34 0.05 0.00 0.17 - - - 0.12 0.21 0.93
Other Noncurrent Operating Liabilities		 0.39 - - - - 1.32 0.98 0.41 0.18 18 6.56
Commitments & Contingencies		 0.00 - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -109 31 16 31 120 68 76 41 72 14 98
Total Preferred & Common Equity		 -109 31 16 31 120 68 76 41 43 -16 63
Total Common Equity		 -109 31 16 31 120 68 76 41 43 -16 63
Common Stock		 6.92 162 164 204 323 327 391 444 33 68 136
Retained Earnings		 -116 -131 -148 -173 -203 -259 -315 -403 7.40 -86 -73
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 -0.00 0.00 -0.00 0.03 0.01 - -0.39 -1.64 -2.60
Other Equity Adjustments		 - - - - - - - - 2.66 3.10 3.10
Noncontrolling Interest		 - - - - - - - - 30 30 35

Quarterly Balance Sheets for Gyre Therapeutics

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 83 31 19 12 9.96 122 121 125 130
Total Current Assets		 81 30 14 7.62 5.13 63 54 55 68
Cash & Equivalents		 75 23 8.10 6.92 2.23 30 16 16 15
Short-Term Investments		 0.00 0.00 - - - 7.57 9.00 9.23 15
Note & Lease Receivable		 - - - - - 15 19 19 2.14
Accounts Receivable		 5.00 5.00 5.00 0.00 1.20 1.29 1.29 1.29 20
Inventories, net		 - - - - - 4.94 5.64 6.38 7.88
Prepaid Expenses		 0.91 2.16 0.92 0.70 1.70 1.79 1.15 1.05 8.16
Plant, Property, & Equipment, net		 0.16 0.12 0.00 0.00 0.00 24 24 24 24
Total Noncurrent Assets		 1.90 0.65 4.74 4.77 4.83 36 44 46 38
Intangible Assets		 - - - - - 0.20 0.19 0.18 5.08
Noncurrent Deferred & Refundable Income Taxes		 - - - - - 5.00 5.08 5.16 5.82
Other Noncurrent Operating Assets		 1.90 0.65 0.19 0.17 0.17 26 34 36 27
Total Liabilities & Shareholders' Equity		 83 31 19 12 9.96 122 121 125 130
Total Liabilities		 4.31 1.64 11 7.40 6.45 33 28 27 25
Total Current Liabilities		 4.31 1.64 6.84 2.79 1.78 19 16 15 19
Accounts Payable		 1.04 0.04 0.02 0.01 0.16 0.33 0.27 0.30 0.12
Accrued Expenses		 0.95 0.18 0.74 2.07 0.92 11 11 9.55 17
Current Deferred Revenue		 0.00 0.00 - - - 0.04 0.06 0.04 0.03
Current Deferred & Payable Income Tax Liabilities		 - - - - - 6.47 2.26 2.84 0.57
Other Current Liabilities		 1.42 0.38 5.00 0.00 0.00 1.88 2.47 1.98 1.03
Total Noncurrent Liabilities		 0.00 0.00 4.55 4.61 4.66 14 12 12 6.50
Noncurrent Deferred Revenue		 - - - - - 0.20 0.19 0.19 0.91
Other Noncurrent Operating Liabilities		 0.00 0.00 4.55 4.61 4.66 14 12 12 5.59
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 79 29 -26 -28 3.52 89 93 98 104
Total Preferred & Common Equity		 79 29 -26 -28 3.52 57 60 63 68
Total Common Equity		 79 29 -26 -28 -30 57 60 63 68
Common Stock		 445 400 385 385 385 133 134 134 138
Retained Earnings		 -366 -370 -411 -413 -415 -78 -74 -73 -71
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -1.74 -2.01 -0.95 -2.49
Other Equity Adjustments		 - - - - - 3.10 3.10 3.10 3.10
Noncontrolling Interest		 - - - - - 32 33 35 36

Annual Metrics And Ratios for Gyre Therapeutics

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 246.65% -3.47% -77.20% 155.14% -99.41% -100.00% 0.00% -64.97% 1,293.98% 10.91% -6.78%
EBITDA Growth		 25.33% -95.23% -50.23% -8.09% -55.54% -69.66% -0.18% -53.07% 111.20% -883.44% 130.25%
EBIT Growth		 25.80% -83.81% -47.94% -6.88% -54.99% -69.35% -0.16% -53.21% 109.88% -998.10% 127.78%
NOPAT Growth		 25.80% -83.81% -47.94% -6.88% -54.99% -69.35% -0.16% -53.21% 106.86% -1,215.66% 126.48%
Net Income Growth		 33.64% -123.23% -14.79% -27.24% -39.40% -83.59% -1.93% -56.35% 104.91% -2,081.46% 120.94%
EPS Growth		 34.08% -123.23% -14.79% 65.75% 64.03% -71.64% 36.30% 2.05% 101.05% -4,800.00% 103.55%
Operating Cash Flow Growth		 -1.83% -199.23% 3.38% -7.95% -43.19% -52.74% -26.22% -52.15% 112.75% 142.50% -114.06%
Free Cash Flow Firm Growth		 -84.53% 6.56% -38.18% 0.46% -75.91% -25.38% -34.79% -43.70% 21.12% 7.41% 68.20%
Invested Capital Growth		 74.23% 39.63% 15.29% -81.19% 87.90% -3,576.29% 31.67% 1.13% 916.42% -4.42% 59.53%
Revenue Q/Q Growth		 0.00% -37.12% -8.70% 31.87% -98.15% 0.00% 0.00% 20.93% 3,062.96% -39.59% 0.69%
EBITDA Q/Q Growth		 -312.87% -344.62% -2.98% -3.00% -21.04% 0.00% 0.00% -1.63% -16.00% -2,244.91% 128.68%
EBIT Q/Q Growth		 -448.45% -375.71% -2.69% -2.88% -20.94% 0.00% 0.00% -1.70% -23.47% -4,116.94% 126.26%
NOPAT Q/Q Growth		 -343.91% -293.00% -2.69% -2.88% -20.94% 0.00% 0.00% -1.70% -62.84% -0.25% 123.40%
Net Income Q/Q Growth		 -423.18% -275.93% 7.53% -10.25% -20.36% 0.00% 0.00% -1.64% -63.70% -589.30% 121.40%
EPS Q/Q Growth		 0.00% -275.93% 7.53% -36.70% -28.23% 0.00% 0.00% 10.03% -92.11% -58.43% 103.42%
Operating Cash Flow Q/Q Growth		 -133.91% -19.23% 0.89% -7.20% -10.42% 2.07% -34.19% 5.03% 121.66% -60.06% -246.99%
Free Cash Flow Firm Q/Q Growth		 -178.34% -294.03% 5.80% -18.76% -9.96% 0.00% 0.00% 0.00% -3,916.64% -7.24% 88.59%
Invested Capital Q/Q Growth		 -78.52% 19.68% -979.59% 31.71% -134.12% 0.00% 0.00% -51.95% 648.48% 3,388.36% -2.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 56.26% -0.57% 95.31% 95.91% 96.33%
EBITDA Margin		 -376.67% -761.83% -5,019.80% -2,126.62% -561,216.67% 0.00% -273.21% -1,193.84% 9.60% -67.78% 21.99%
Operating Margin		 -414.18% -788.69% -5,117.29% -2,143.61% -563,700.00% 0.00% -273.87% -1,197.79% 9.00% -59.26% 15.28%
EBIT Margin		 -414.18% -788.69% -5,117.29% -2,143.61% -563,700.00% 0.00% -273.87% -1,197.79% 8.49% -68.76% 20.49%
Profit (Net Income) Margin		 -364.75% -843.54% -4,246.87% -2,117.98% -500,916.67% 0.00% -268.48% -1,198.32% 4.22% -75.35% 16.92%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 45.84% 111.06% 77.09%
Interest Burden Percent		 88.07% 106.96% 82.99% 98.80% 88.86% 96.34% 98.03% 100.04% 108.36% 98.66% 107.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.16% 0.00% 22.91%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.44% -102.30% 21.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.17% 28.64% 3.28%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12.82% -11.15% -1.12%
Return on Equity (ROE)		 -9.86% -95.39% -71.35% -92.05% -39.88% -58.61% -77.89% -150.11% 7.61% -113.45% 20.24%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -103.28% -97.78% -24.52%
Operating Return on Assets (OROA)		 -10.09% -38.07% -37.95% -56.24% -41.14% 0.00% -59.33% -116.80% 12.37% -77.51% 17.91%
Return on Assets (ROA)		 -8.89% -40.72% -31.49% -55.57% -36.56% 0.00% -58.16% -116.85% 6.14% -84.93% 14.80%
Return on Common Equity (ROCE)		 -1.86% 240.18% -71.35% -92.05% -39.88% -58.61% -77.89% -150.11% 5.62% -20.10% 5.43%
Return on Equity Simple (ROE_SIMPLE)		 6.05% -46.98% -105.44% -70.06% -25.06% -80.75% -73.93% -214.01% 10.15% 540.06% 28.27%
Net Operating Profit after Tax (NOPAT)		 -5.26 -9.66 -14 -15 -24 -40 -40 -62 4.22 -47 12
NOPAT Margin		 -289.92% -552.08% -3,582.11% -1,500.53% -394,590.00% 0.00% -191.71% -838.45% 4.12% -41.48% 11.78%
Net Nonoperating Expense Percent (NNEP)		 -1.88% -29.77% -10.65% -25.23% -8.35% -15.31% -20.26% -41.02% 0.27% -130.94% 18.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -337.38% 12.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 43.74% 100.57% 4.69% 4.09% 3.67%
SG&A Expenses to Revenue		 223.66% 548.23% 2,321.30% 981.63% 205,900.00% 0.00% 77.24% 258.42% 16.98% 12.92% 15.23%
R&D to Revenue		 290.51% 340.46% 2,895.99% 1,261.98% 357,900.00% 0.00% 252.89% 938.80% 16.31% 85.40% 11.37%
Operating Expenses to Revenue		 514.18% 888.69% 5,217.29% 2,243.61% 563,800.00% 0.00% 330.13% 1,197.22% 86.32% 155.17% 81.04%
Earnings before Interest and Taxes (EBIT)		 -7.51 -14 -20 -22 -34 -57 -57 -88 8.69 -78 22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.83 -13 -20 -22 -34 -57 -57 -88 9.82 -77 23
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.30 0.13 0.50 0.21 0.32 0.48 0.18 0.39 0.00 17.87
Price to Tangible Book Value (P/TBV)		 0.00 0.30 0.13 0.50 0.21 0.32 0.48 0.18 0.39 0.00 17.95
Price to Revenue (P/Rev)		 0.00 5.37 5.15 15.18 4,128.55 0.00 1.75 1.03 0.16 8.60 10.70
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.22 0.00 93.64
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 271.09% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.86% 0.00% 1.07%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 23.05 15.89
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21 9.14 10.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.15 0.00 49.01
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.43 0.00 52.61
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.01 0.00 91.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.98 40.03 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 1.07 1.21 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.11 -1.05 -1.06 -1.01 -1.05 -1.10 -1.10 -0.64 -0.39 -0.34
Leverage Ratio		 1.11 2.34 2.27 1.66 1.09 1.19 1.34 1.28 1.24 1.34 1.37
Compound Leverage Factor		 0.98 2.51 1.88 1.64 0.97 1.14 1.31 1.29 1.34 1.32 1.47
Debt to Total Capital		 0.00% 51.78% 54.70% 14.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 51.78% 54.70% 14.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -22,921.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 41.12% 120.17% 35.65%
Common Equity to Total Capital		 23,021.47% 48.22% 45.30% 85.82% 100.00% 100.00% 100.00% 100.00% 58.88% -20.17% 64.35%
Debt to EBITDA		 0.00 -2.53 -0.97 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.44 0.86 1.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -3.49 -1.36 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.37 1.20 2.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -2.59 -6.65 -5.96 0.96 -4.34 -4.34 -14.09 2.99 13.50 26.17
Noncontrolling Interest Sharing Ratio		 81.17% 351.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.21% 82.29% 73.15%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.89 1.82 1.71 4.48 25.83 3.32 5.03 3.63 4.06 2.85 3.32
Quick Ratio		 0.70 0.87 0.78 3.71 25.02 3.18 4.65 3.44 3.46 2.51 2.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -10 -14 -14 -25 -32 -43 -62 -49 -45 -14
Operating Cash Flow to CapEx		 0.00% -7,028.68% 0.00% -86,695.65% -7,593.88% 0.00% 0.00% -9,982.72% 214.18% 329.71% -190.23%
Free Cash Flow to Firm to Interest Expense		 0.00 -10.92 0.00 0.00 0.00 0.00 0.00 -1,579.28 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -19.91 0.00 0.00 0.00 0.00 0.00 -2,147.56 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -20.20 0.00 0.00 0.00 0.00 0.00 -2,169.08 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.05 0.01 0.03 0.00 0.00 0.22 0.10 1.46 1.13 0.87
Accounts Receivable Turnover		 9.72 5.96 1.53 0.00 0.00 0.00 2.29 2.86 0.00 0.00 5.83
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.89 0.73
Fixed Asset Turnover		 2.28 2.18 0.70 2.83 0.02 0.00 56.85 10.46 10.95 5.53 4.48
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 1.79 1.20 1.47 19.44 16.78
Days Sales Outstanding (DSO)		 37.55 61.22 239.22 0.00 0.00 0.00 159.54 127.61 0.00 0.00 62.59
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 409.52 498.91
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 203.35 305.40 249.06 18.78 21.76
Cash Conversion Cycle (CCC)		 37.55 61.22 239.22 0.00 0.00 0.00 -43.81 -177.79 -249.06 390.75 539.75
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.07 -1.25 -1.06 -1.92 -0.23 -8.53 -5.83 -5.76 47 45 72
Invested Capital Turnover		 -0.36 -1.05 -0.35 -0.68 -0.01 0.00 -2.92 -1.27 4.96 2.47 1.81
Increase / (Decrease) in Invested Capital		 5.96 0.82 0.19 -0.86 1.69 -8.30 2.70 0.07 53 -2.08 27
Enterprise Value (EV)		 0.00 -23 -15 -17 -95 -55 -45 -39 21 1,036 1,140
Market Capitalization		 0.00 9.40 2.06 15 25 22 37 7.55 17 976 1,132
Book Value per Share		 ($3.19) $2.75 $1.34 $7.14 $10.04 $5.68 $3.44 $1.31 $1.35 ($0.42) $0.68
Tangible Book Value per Share		 ($3.19) $2.75 $1.34 $7.14 $10.04 $5.68 $3.44 $1.31 $1.34 ($0.42) $0.67
Total Capital		 -0.48 65 35 36 120 68 76 41 72 78 98
Total Debt		 0.00 34 19 5.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.59 -33 -17 -33 -120 -77 -82 -47 -25 -34 -27
Capital Expenditures (CapEx)		 -0.10 0.27 -2.10 0.02 0.38 0.00 0.00 0.84 4.99 7.85 1.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.86 -1.61 -1.57 -2.32 -0.99 -9.70 -7.64 -9.54 12 3.67 19
Debt-free Net Working Capital (DFNWC)		 -0.27 65 35 35 119 67 72 37 37 37 45
Net Working Capital (NWC)		 -0.27 31 16 30 119 67 72 37 37 37 45
Net Nonoperating Expense (NNE)		 1.36 5.10 2.65 6.29 6.38 15 16 26 -0.10 38 -5.44
Net Nonoperating Obligations (NNO)		 -1.59 -33 -17 -33 -120 -77 -82 -47 -25 -34 -27
Total Depreciation and Amortization (D&A)		 0.68 0.47 0.39 0.17 0.15 0.15 0.14 0.29 1.13 1.11 1.59
Debt-free, Cash-free Net Working Capital to Revenue		 -102.59% -91.83% -394.24% -228.00% -16,450.00% 0.00% -36.47% -130.01% 11.96% 3.23% 17.59%
Debt-free Net Working Capital to Revenue		 -14.67% 3,696.29% 8,761.65% 3,482.81% 1,986,500.00% 0.00% 342.34% 508.46% 36.57% 32.77% 42.81%
Net Working Capital to Revenue		 -14.67% 1,768.11% 3,898.75% 2,983.30% 1,986,500.00% 0.00% 342.34% 508.46% 36.57% 32.77% 42.81%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($14.55) ($49.95) ($21.75) ($7.45) ($2.68) $0.00 ($2.93) ($2.87) ($0.26) ($1.41) $0.14
Adjusted Weighted Average Basic Shares Outstanding		 2.25M 762.01K 1.00M 11.89M 11.97M 0.00 31.33M 31.48M 31.55M 65.83M 85.09M
Adjusted Diluted Earnings per Share		 ($14.55) ($49.95) ($21.75) ($7.45) ($2.68) $0.00 ($2.93) ($2.87) ($0.26) ($1.41) $0.05
Adjusted Weighted Average Diluted Shares Outstanding		 2.25M 762.01K 1.00M 11.89M 11.97M 0.00 31.33M 31.48M 31.55M 65.83M 102.29M
Adjusted Basic & Diluted Earnings per Share		 ($14.55) ($49.95) ($21.75) ($7.45) ($2.68) $0.00 ($2.93) ($2.87) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.25M 295.27K 779.17K 3.42M 11.21M 0.00 19.18M 30.64M 37.76M 85.42M 93.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.26 -9.66 -14 -15 -24 -40 -40 -62 6.44 -47 13
Normalized NOPAT Margin		 -289.92% -552.08% -3,582.11% -1,500.53% -394,590.00% 0.00% -191.71% -838.45% 6.30% -41.09% 11.83%
Pre Tax Income Margin		 -364.75% -843.54% -4,246.87% -2,117.98% -500,916.67% 0.00% -268.48% -1,198.32% 9.20% -67.84% 21.95%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -14.38 0.00 0.00 0.00 0.00 0.00 -2,253.69 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -10.06 0.00 0.00 0.00 0.00 0.00 -1,577.58 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -14.66 0.00 0.00 0.00 0.00 0.00 -2,275.21 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -10.35 0.00 0.00 0.00 0.00 0.00 -1,599.10 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Gyre Therapeutics

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 4,059.67% 3,039.92% 0.00% 0.00% -73.25% 8.99% -13.99% -20.45% 2.67% -18.82%
EBITDA Growth		 79.61% -6.91% 143.69% -88.52% 326.94% -366.92% 97.36% 1.18% -66.81% 100.82% -59.91%
EBIT Growth		 79.52% -10.57% 141.41% -89.13% 321.27% -350.27% 99.66% 2.68% -70.20% 100.35% -62.86%
NOPAT Growth		 79.52% -10.57% 143.55% -93.78% 336.93% -307.98% 43.37% -23.43% -64.10% 100.69% -71.50%
Net Income Growth		 80.65% -37.23% 129.01% -92.70% 253.77% -261.95% 135.59% 20.37% -61.97% 100.56% -62.42%
EPS Growth		 80.00% -54.69% 106.52% -98.78% 131.25% -52.53% 0.00% -50.00% -80.00% 0.00% -100.00%
Operating Cash Flow Growth		 66.31% 339.30% 186.45% 136.87% 204.19% -92.06% -72.31% -221.18% -77.24% -182.08% -104.47%
Free Cash Flow Firm Growth		 42.62% -379.70% 54.13% -81.08% 199.06% 9.43% -1,723.13% -869.62% -608.83% 57.58% 53.73%
Invested Capital Growth		 265.74% 916.42% 90.39% -152.56% -79.49% -4.42% 7,020.46% 3,639.73% 5,592.94% 59.53% 44.72%
Revenue Q/Q Growth		 0.00% 0.00% -75.44% 17.64% 9.25% -15.27% -54.09% -7.17% 1.04% 9.35% -20.86%
EBITDA Q/Q Growth		 -109.93% -321.24% 129.51% -7.09% 96.47% -966.69% 116.51% -52.37% -35.55% -78.53% 523.64%
EBIT Q/Q Growth		 -110.03% -334.77% 127.10% -7.95% 104.02% -984.70% 115.73% -52.66% -40.78% -89.49% 1,194.69%
NOPAT Q/Q Growth		 -107.02% -334.77% 128.50% -28.52% 167.47% -848.64% 111.88% -61.82% 25.41% -85.70% 316.15%
Net Income Q/Q Growth		 -109.46% -471.21% 115.12% -10.60% 99.20% -1,444.57% 110.81% -54.32% -37.06% -80.08% 556.24%
EPS Q/Q Growth		 -109.76% -518.75% 103.03% -33.33% 150.00% -3,120.00% 102.11% -66.67% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 40.81% 681.26% -75.37% -56.48% 67.26% -55.68% -92.37% -290.46% 131.42% -259.79% 95.32%
Free Cash Flow Firm Q/Q Growth		 -129.45% -400.44% 96.34% 450.75% 54.15% -557.58% 12.03% -48.07% -1.91% 61.86% 19.62%
Invested Capital Q/Q Growth		 71.35% 648.48% -101.58% -159.49% 166.86% 3,388.36% 14.35% 32.73% 7.53% -2.25% 3.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 96.06% 95.49% 96.33% 96.30% 95.40% 96.40% 96.95% 96.24% 95.78% 95.95%
EBITDA Margin		 0.00% -21.27% 25.56% 20.19% 36.31% -371.38% 46.29% 23.75% 15.15% 2.97% 23.44%
Operating Margin		 0.00% -22.13% 26.73% 16.96% 39.84% -337.53% 29.70% 12.93% 16.61% 2.14% 10.30%
EBIT Margin		 0.00% -22.13% 24.42% 19.10% 35.68% -372.51% 44.73% 22.81% 13.37% 1.28% 21.01%
Profit (Net Income) Margin		 0.00% -27.49% 16.91% 12.85% 23.44% -371.95% 36.56% 17.99% 11.21% 2.04% 16.93%
Tax Burden Percent		 100.00% 122.36% 67.25% 64.40% 67.13% 100.70% 79.60% 75.19% 72.67% 73.70% 80.56%
Interest Burden Percent		 94.54% 101.51% 103.02% 104.48% 97.87% 99.16% 102.70% 104.90% 115.35% 215.64% 100.00%
Effective Tax Rate		 0.00% 0.00% 32.75% 35.60% 32.87% 0.00% 20.40% 24.81% 27.33% 26.30% 19.44%
Return on Invested Capital (ROIC)		 0.00% -76.77% 0.00% 1,955.34% 1,326.02% -582.67% 107.96% 32.72% 33.95% 2.86% 13.28%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -42.96% 0.00% 1,953.96% 1,334.38% -457.13% 92.51% 19.70% 35.57% 2.43% 7.62%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 27.31% 0.00% -1,913.52% -1,027.11% 178.02% -43.74% -6.42% -9.53% -0.83% -2.65%
Return on Equity (ROE)		 0.00% -49.46% 133.95% 41.82% 298.91% -404.65% 64.22% 26.31% 24.43% 2.03% 10.63%
Cash Return on Invested Capital (CROIC)		 20.25% -103.28% 0.00% 0.00% -1,107.71% -97.78% -191.05% -172.10% -335.71% -24.52% -24.01%
Operating Return on Assets (OROA)		 0.00% -32.24% 104.59% 62.14% 326.95% -419.90% 73.52% 38.18% 20.77% 1.12% 16.80%
Return on Assets (ROA)		 0.00% -40.05% 72.46% 41.81% 214.80% -419.27% 60.10% 30.11% 17.41% 1.78% 13.53%
Return on Common Equity (ROCE)		 0.00% -36.50% 4.40% 25.25% -3.79% -71.68% 20.50% 8.57% 8.00% 0.55% 6.87%
Return on Equity Simple (ROE_SIMPLE)		 40.45% 0.00% -88.88% 87.57% -352.60% 0.00% -140.82% -130.89% -132.40% 0.00% 17.17%
Net Operating Profit after Tax (NOPAT)		 -3.62 -16 4.48 3.20 8.57 -64 6.42 2.45 3.08 0.44 1.83
NOPAT Margin		 0.00% -15.49% 17.97% 10.92% 26.74% -236.27% 23.64% 9.72% 12.07% 1.58% 8.30%
Net Nonoperating Expense Percent (NNEP)		 -2.89% -33.81% -1.23% 1.38% -8.36% -125.54% 15.45% 13.02% -1.61% 0.43% 5.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -459.84% - - - 0.45% 1.76%
Cost of Revenue to Revenue		 0.00% 3.94% 4.51% 3.67% 3.70% 4.60% 3.60% 3.05% 3.76% 4.22% 4.05%
SG&A Expenses to Revenue		 0.00% 4.11% 6.98% 5.83% 3.61% 37.04% 12.51% 13.57% 15.00% 19.60% 22.46%
R&D to Revenue		 0.00% 4.25% 10.57% 12.17% 9.39% 322.94% 8.03% 13.30% 10.89% 13.32% 14.03%
Operating Expenses to Revenue		 0.00% 118.20% 68.76% 79.37% 58.11% 430.99% 66.69% 84.29% 79.63% 93.39% 85.64%
Earnings before Interest and Taxes (EBIT)		 -5.17 -22 6.09 5.60 11 -101 12 5.75 3.41 0.36 4.64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.13 -22 6.37 5.92 12 -101 13 5.99 3.86 0.83 5.17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.54 0.39 0.00 0.00 0.00 0.00 26.36 16.90 18.54 17.87 10.61
Price to Tangible Book Value (P/TBV)		 0.54 0.39 0.00 0.00 0.00 0.00 26.45 16.96 18.60 17.95 11.46
Price to Revenue (P/Rev)		 4.91 0.16 0.06 0.09 0.10 8.60 12.91 9.14 11.15 10.70 7.18
Price to Earnings (P/E)		 1.34 7.22 0.41 0.00 0.00 0.00 0.00 0.00 0.00 93.64 99.67
Dividend Yield		 283.73% 271.09% 690.82% 406.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 74.90% 13.86% 244.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.07% 1.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.45 0.00 0.00 38.32 23.05 28.94 15.06 16.10 15.89 9.80
Enterprise Value to Revenue (EV/Rev)		 0.00 0.21 0.26 0.25 0.26 9.14 12.86 9.21 11.25 10.78 7.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 2.15 1.04 0.00 13.78 0.00 0.00 0.00 0.00 49.01 46.93
Enterprise Value to EBIT (EV/EBIT)		 0.00 2.43 1.08 0.00 25.44 0.00 0.00 0.00 0.00 52.61 52.73
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 5.01 1.42 0.00 0.00 0.00 0.00 0.00 0.00 91.50 92.43
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 1.98 1.00 0.79 0.76 40.03 81.05 123.37 477.09 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 2.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.64 -1.25 -0.98 -0.77 -0.39 -0.47 -0.33 -0.27 -0.34 -0.35
Leverage Ratio		 1.22 1.24 1.71 1.14 1.25 1.34 1.46 1.36 1.33 1.37 1.30
Compound Leverage Factor		 1.15 1.26 1.77 1.19 1.22 1.32 1.50 1.42 1.53 2.95 1.30
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 947.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 41.12% 452.81% 666.85% 0.00% 120.17% 36.20% 35.35% 35.84% 35.65% 34.69%
Common Equity to Total Capital		 100.00% 58.88% -352.81% -566.85% -847.09% -20.17% 63.80% 64.65% 64.16% 64.35% 65.31%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -10.27 1.78 -21.98 -31.07 -33.53 12.84 27.76 22.78 26.75 25.61 17.60
Noncontrolling Interest Sharing Ratio		 0.00% 26.21% 96.72% 39.63% 101.27% 82.29% 68.08% 67.42% 67.26% 73.15% 35.38%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.40 4.06 2.05 2.73 2.88 2.85 3.22 3.44 3.72 3.32 3.60
Quick Ratio		 17.09 3.46 1.91 2.48 1.92 2.51 2.78 2.89 3.12 2.86 2.76
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -69 -2.51 8.80 14 -62 -46 -68 -69 -26 -21
Operating Cash Flow to CapEx		 0.00% 9,462.64% 597.99% 193.47% 470.64% 155.77% 1,593.37% -443.70% 247.28% 0.00% -106.61%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 1.46 4.28 3.25 9.16 1.13 1.64 1.67 1.55 0.87 0.80
Accounts Receivable Turnover		 1.06 0.00 45.44 0.00 60.58 0.00 36.80 0.00 84.47 5.83 9.29
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.89 0.00 0.00 0.00 0.73 0.59
Fixed Asset Turnover		 5.32 10.95 294.70 0.00 0.00 5.53 9.82 0.00 0.00 4.48 4.28
Accounts Payable Turnover		 1.67 1.47 2.17 11.89 74.18 19.44 25.95 30.31 17.17 16.78 16.81
Days Sales Outstanding (DSO)		 345.02 0.00 8.03 0.00 6.03 0.00 9.92 0.00 4.32 62.59 39.29
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 409.52 0.00 0.00 0.00 498.91 615.72
Days Payable Outstanding (DPO)		 219.03 249.06 168.31 30.69 4.92 18.78 14.06 12.04 21.26 21.76 21.71
Cash Conversion Cycle (CCC)		 125.99 -249.06 -160.28 -30.69 1.10 390.75 -4.15 -12.04 -16.94 539.75 633.29
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.29 47 -0.74 -1.93 1.29 45 51 68 73 72 74
Invested Capital Turnover		 2.59 4.96 -29.83 179.03 49.59 2.47 4.57 3.37 2.81 1.81 1.60
Increase / (Decrease) in Invested Capital		 10 53 6.99 -5.60 -5.00 -2.08 52 70 72 27 23
Enterprise Value (EV)		 -7.23 21 33 40 49 1,036 1,488 1,028 1,182 1,140 729
Market Capitalization		 16 17 7.82 13 18 976 1,493 1,020 1,172 1,132 723
Book Value per Share		 $0.93 $1.35 ($0.69) ($0.75) ($0.78) ($0.42) $0.66 $0.71 $0.68 $0.68 $0.73
Tangible Book Value per Share		 $0.93 $1.34 ($0.69) ($0.75) ($0.78) ($0.42) $0.66 $0.70 $0.67 $0.67 $0.67
Total Capital		 29 72 7.36 5.00 3.52 78 89 93 98 98 104
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -23 -25 -8.10 -6.92 -2.23 -34 -37 -25 -25 -27 -30
Capital Expenditures (CapEx)		 0.00 0.45 1.74 2.34 1.61 2.16 0.18 1.24 0.70 -0.20 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 5.51 12 -0.93 -2.10 1.12 3.67 5.89 13 15 19 20
Debt-free Net Working Capital (DFNWC)		 29 37 7.17 4.83 3.35 37 43 38 40 45 49
Net Working Capital (NWC)		 29 37 7.17 4.83 3.35 37 43 38 40 45 49
Net Nonoperating Expense (NNE)		 1.27 12 0.26 -0.57 1.06 37 -3.51 -2.09 0.22 -0.13 -1.90
Net Nonoperating Obligations (NNO)		 -23 -25 -8.10 -6.92 -2.23 -34 -37 -25 -25 -27 -30
Total Depreciation and Amortization (D&A)		 0.04 0.87 0.29 0.32 0.20 0.31 0.43 0.24 0.45 0.47 0.54
Debt-free, Cash-free Net Working Capital to Revenue		 170.44% 11.96% -0.73% -1.35% 0.60% 3.23% 5.09% 11.51% 14.28% 17.59% 19.44%
Debt-free Net Working Capital to Revenue		 884.42% 36.57% 5.67% 3.10% 1.78% 32.77% 37.37% 34.00% 38.17% 42.81% 49.14%
Net Working Capital to Revenue		 884.42% 36.57% 5.67% 3.10% 1.78% 32.77% 37.37% 34.00% 38.17% 42.81% 49.14%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.16) ($0.98) $0.01 ($0.07) ($0.04) ($1.54) $0.09 $0.04 $0.01 $0.00 $0.03
Adjusted Weighted Average Basic Shares Outstanding		 31.48M 63.59M 37.76M 37.80M 37.98M 65.83M 83.27M 85.50M 85.64M 85.09M 86.42M
Adjusted Diluted Earnings per Share		 ($0.16) ($0.99) $0.01 ($0.07) ($0.04) ($1.51) $0.03 $0.01 $0.01 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 31.48M 75.69M 37.98M 37.80M 37.98M 65.83M 102.59M 104.33M 102.64M 102.29M 101.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.49M 37.76M 37.76M 37.97M 37.98M 85.42M 85.51M 93.42M 93.52M 93.61M 93.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.62 24 4.48 3.20 8.92 -64 6.42 2.50 3.08 0.44 1.83
Normalized NOPAT Margin		 0.00% 23.99% 17.97% 10.92% 27.84% -236.27% 23.64% 9.93% 12.07% 1.58% 8.30%
Pre Tax Income Margin		 0.00% -22.46% 25.15% 19.96% 34.92% -369.38% 45.93% 23.92% 15.42% 2.77% 21.01%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 378.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 378.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Gyre Therapeutics’ Q1 2025 results show a mixed picture: sequential operational improvement and cheaper valuation but continued reliance on negative cash flows and contracting revenue.

  • Zero debt on the balance sheet with a current ratio of 3.6×, supporting liquidity
  • Sequential uptick in profitability: Q1 2025 EBITDA rose 5.2% QoQ and EBIT gained 11.9% QoQ
  • Valuation multiples have normalized: P/B down to 10.6× from 26.4× a year ago
  • Robust Altman Z-Score of 17.6, well above distress thresholds
  • Profit (net income) margin remains healthy at 16.9% in Q1 2025
  • R&D spend is elevated at 14.0% of revenue, reflecting continued pipeline investment
  • Nonoperating items and one-offs continue to swing quarterly net income
  • Revenue contracted 18.8% year-over-year in Q1 2025
  • Operating cash flow turned negative (-$0.15 M) after previous positive quarters
  • Free cash flow to firm remains deeply negative at -$21.2 M in Q1 2025

Investors should weigh the improving operational momentum and more attractive valuation against ongoing cash burn and a backdrop of declining top-line growth.

07/24/25 10:33 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Gyre Therapeutics' Financials

When does Gyre Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Gyre Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gyre Therapeutics' net income changed over the last 10 years?

Gyre Therapeutics' net income appears to be on an upward trend, with a most recent value of $17.90 million in 2024, falling from -$6.61 million in 2014. The previous period was -$85.48 million in 2023. Check out Gyre Therapeutics' forecast to explore projected trends and price targets.

What is Gyre Therapeutics' operating income?
Gyre Therapeutics' total operating income in 2024 was $16.16 million, based on the following breakdown:
  • Total Gross Profit: $101.87 million
  • Total Operating Expenses: $85.71 million
How has Gyre Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Gyre Therapeutics' total revenue changed from $1.81 million in 2014 to $105.76 million in 2024, a change of 5,733.3%.

How much debt does Gyre Therapeutics have?

Gyre Therapeutics' total liabilities were at $27.00 million at the end of 2024, a 29.1% decrease from 2023, and a 681.4% increase since 2014.

How much cash does Gyre Therapeutics have?

In the past 10 years, Gyre Therapeutics' cash and equivalents has ranged from $1.54 million in 2014 to $44.35 million in 2021, and is currently $11.81 million as of their latest financial filing in 2024.

How has Gyre Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Gyre Therapeutics' book value per share changed from -3.19 in 2014 to 0.68 in 2024, a change of -121.2%.


Related Companies

This page (NASDAQ:GYRE) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
Why Elon put $51 million into this
A single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...
True Market Insiders | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Treasury Secretary Bessent Is Betting Big on Gold
When the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...
Golden Portfolio | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Think you missed gold’s boom? Think again
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...
Investors Alley | Sponsored
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored